Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis? (2018)

Peer-Reviewed Study · Chandler RE · February 2018

Chandler RE, 2018-02: Review of 48 serious neurological adverse-event reports in VigiBase for ivermectin used outside the onchocerciasis indication, leaving 28 after exclusions. It finds supportive evidence of causation, including drug in brain tissue in one case and symptom recurrence on re-exposure in three.

Within the remaining 28 cases, there is supportive evidence for a causative role of ivermectin including presence of the drug in brain tissue in one case and recurrence of symptoms on repeated exposure in three cases.

Chandler RE, 2018-02: Review of 48 serious neurological adverse-event reports in VigiBase for ivermectin used outside the onchocerciasis indication, leaving 28 after exclusions. It finds supportive evidence of causation, including drug in brain tissue in one case and symptom recurrence on re-exposure in three. C4 pharmacovigilance (WHO VigiBase). Study type: case series from an international spontaneous-reporting database with clinical review; N=48 reports, 28 retained; multiple countries. Dose: not stated in the abstract; the reports cover several indications. Comparator: none. Funder: not stated in the PubMed record (author affiliated with Uppsala Monitoring Centre per the paper, not stated in the abstract captured). Declared conflicts: none in the PubMed record. This is the document that carries the neurotoxicity question outside the onchocerciasis/Loa loa setting. Study type: uncontrolled series.